UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Physical Mundane as Topos: Walking/Dwelling/Using as Rhetorical Invention

College composition and communication, 2016-12, Vol.68 (2), p.266-291

Bacha, Jeffrey A.

2016

Volltextzugriff (PDF)

Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials

Neuro-oncology (Charlottesville, Va.), 2021-02, Vol.23 (2), p.189-198

2021

Volltextzugriff (PDF)

Dianhydrogalactitol induces replication-dependent DNA damage in tumor cells preferentially resolved by homologous recombination

Cell death & disease, 2018-10, Vol.9 (10), p.1016-10, Article 1016

2018

Volltextzugriff (PDF)

Abstract 2157: Enhanced in vitro activity of dianhydrogalactitol (VAL-083) in combination with platinum drugs: Impact of p53 and platinum-resistance

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2157-2157

2016

Volltextzugriff (PDF)

Taxonomies, Folksonomies, and Semantics: Establishing Functional Meaning in Navigational Structures

Journal of technical writing and communication, 2012-07, Vol.42 (3), p.249-263

Bacha, Jeffrey A.

2012

Volltextzugriff (PDF)

Mapping Use, Storytelling, and Experience Design: User-Network Tracking as a Component of Usability and Sustainability

Journal of business and technical communication, 2018-04, Vol.32 (2), p.198-228

Bacha, Jeffrey A.

2018

Volltextzugriff (PDF)

Mapping Use, Storytelling, and Experience Design

Journal of business and technical communication, 2018-04, Vol.32 (2), p.198-228

Bacha, Jeffrey A

2018

Volltextzugriff (PDF)

Phase 2 clinical trial of VAL-083 as first-line treatment in newly-diagnosed MGMT-unmethylated glioblastoma multiforme (GBM): Halfway report

Glioma, 2019-01, Vol.2 (4), p.167-173

2019

Volltextzugriff (PDF)

Abstract P053: VAL-083 (dianhydrogalactitol) synergizes with PARP inhibitors in BRCA-proficient and BRCA-deficient ovarian cancer models

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P053-P053

2021

Volltextzugriff (PDF)

Abstract 1369: Dianhydrogalactitol (VAL-083) synergizes with topoisomerase inhibitors to overcome homologous recombination repair activity in glioblastoma and prostate cancer cells

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1369-1369

2020

Volltextzugriff (PDF)

Abstract CT137: A pilot pharmacokinetic study of VAL413 in patients with recurrent pediatric solid tumors

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT137-CT137

2020

Volltextzugriff (PDF)

A pilot clinical study of oral irinotecan HCl (VAL-413) in patients with recurrent pediatric solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS10073-TPS10073

2023

Volltextzugriff (PDF)

Abstract P081: In vitro activity and efficacy of novel dual PARP-HDAC inhibitors

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P081-P081

2021

Volltextzugriff (PDF)

Abstract NT-109: VAL-083 (DIANHYDROGALACTITOL) SYNERGIZES WITH PARP INHIBITORS IN BRCA-PROFICIENT AND BRCA-DEFICIENT OVARIAN CANCER MODELS

Clinical cancer research, 2019-11, Vol.25 (22_Supplement), p.NT-109-NT-109

2019

Volltextzugriff (PDF)

A pilot clinical study of VAL-413 (oral irinotecan HCl) in patients with recurrent pediatric solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS10063-TPS10063

2022

Volltextzugriff (PDF)

A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma

Clinical cancer research, 2023-09, Vol.29 (17), p.3541-3553

2023

Volltextzugriff (PDF)

Abstract 3499: Dianhydrogalactitol (VAL-083) in combination with AZD1775 increases survival in diffuse intrinsic pontine glioma (DIPG), in vivo

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3499-3499

2019

Volltextzugriff (PDF)

Abstract 1051: Dianhydrogalactitol (VAL-083) reduces glioblastoma tumor growth upon bevacizumab-induced hypoxia, in vivo

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.1051-1051

2019

Volltextzugriff (PDF)

CTNI-75. A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii60-ii60

2020

Volltextzugriff (PDF)

Abstract CT154: An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and antitumor activity of once-daily oral treatment with EO1001, a novel irreversible pan-ErbB inhibitor with promising brain penetration, in patients with advanced cancer

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT154-CT154

2020

Volltextzugriff (PDF)

DIPG-56. PRECLINICAL STUDIES OF DIANHYDROGALACTITOL (VAL-083) IN DIPG, AS SINGLE AGENT OR AS A COMBINATION WITH RADIATION OR AZD1775

Neuro-oncology (Charlottesville, Va.), 2018-06, Vol.20 (suppl_2), p.i60-i60

2018

Volltextzugriff (PDF)

DDDR-15. UTILIZING DEEP DOCKING AND ARTIFICIAL INTELLIGENCE FOR THE DISCOVERY OF NOVEL PARP1-SELECTIVE INHIBITORS FOR USE AGAINST BRAIN TUMORS

Neuro-oncology (Charlottesville, Va.), 2024-11, Vol.26 (Supplement_8), p.viii128-viii129

2024

Volltextzugriff (PDF)

Abstract 2985: Molecular mechanisms of dianhydrogalactitol (VAL-083) in cancer treatment

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2985-2985

2016

Volltextzugriff (PDF)

Abstract B30: Dianhydrogalactitol (VAL-083) has the potential to overcome major challenges in the treatment of DIPG

Cancer research (Chicago, Ill.), 2018-10, Vol.78 (19_Supplement), p.B30-B30

2018

Volltextzugriff (PDF)

Abstract B15: Dissecting the molecular mechanism of dianhydrogalactitol (VAL-083) activity in cancer treatment

Molecular cancer research, 2017-04, Vol.15 (4_Supplement), p.B15-B15

2017

Volltextzugriff (PDF)

1 – 25 von 161

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(158)
Mit Volltextzugriff
(156)

Publikationsform

Sprache

Englisch
(161)

Erscheinungsjahr

n.n

Thema

Science & Technology
(42)
Life Sciences & Biomedicine
(41)
Humans
(34)
Cardiac & Cardiovascular Systems
(25)
Cardiovascular System & Cardiology
(25)
Heart Defects, Congenital - Surgery
(14)
Pediatrics
(13)
Abstracts
(12)
Child
(12)
Surgery
(12)
Infant, Newborn
(11)
Treatment Outcome
(11)
Male
(10)
Biological And Medical Sciences
(9)
Congenital Heart Disease
(9)
Infant
(9)
Medical Sciences
(9)
Respiratory System
(9)
Female
(8)
Risk Factors
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The Physical Mundane as Topos: Walking/Dwelling/Using as Rhetorical Invention

Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials

Dianhydrogalactitol induces replication-dependent DNA damage in tumor cells preferentially resolved by homologous recombination

Abstract 2157: Enhanced in vitro activity of dianhydrogalactitol (VAL-083) in combination with platinum drugs: Impact of p53 and platinum-resistance

Taxonomies, Folksonomies, and Semantics: Establishing Functional Meaning in Navigational Structures

Mapping Use, Storytelling, and Experience Design: User-Network Tracking as a Component of Usability and Sustainability

Mapping Use, Storytelling, and Experience Design

Phase 2 clinical trial of VAL-083 as first-line treatment in newly-diagnosed MGMT-unmethylated glioblastoma multiforme (GBM): Halfway report

Abstract P053: VAL-083 (dianhydrogalactitol) synergizes with PARP inhibitors in BRCA-proficient and BRCA-deficient ovarian cancer models

Abstract 1369: Dianhydrogalactitol (VAL-083) synergizes with topoisomerase inhibitors to overcome homologous recombination repair activity in glioblastoma and prostate cancer cells

Abstract CT137: A pilot pharmacokinetic study of VAL413 in patients with recurrent pediatric solid tumors

A pilot clinical study of oral irinotecan HCl (VAL-413) in patients with recurrent pediatric solid tumors

Abstract P081: In vitro activity and efficacy of novel dual PARP-HDAC inhibitors

Abstract NT-109: VAL-083 (DIANHYDROGALACTITOL) SYNERGIZES WITH PARP INHIBITORS IN BRCA-PROFICIENT AND BRCA-DEFICIENT OVARIAN CANCER MODELS

A pilot clinical study of VAL-413 (oral irinotecan HCl) in patients with recurrent pediatric solid tumors

A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma

Abstract 3499: Dianhydrogalactitol (VAL-083) in combination with AZD1775 increases survival in diffuse intrinsic pontine glioma (DIPG), in vivo

Abstract 1051: Dianhydrogalactitol (VAL-083) reduces glioblastoma tumor growth upon bevacizumab-induced hypoxia, in vivo

CTNI-75. A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS

Abstract CT154: An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and antitumor activity of once-daily oral treatment with EO1001, a novel irreversible pan-ErbB inhibitor with promising brain penetration, in patients with advanced cancer

DIPG-56. PRECLINICAL STUDIES OF DIANHYDROGALACTITOL (VAL-083) IN DIPG, AS SINGLE AGENT OR AS A COMBINATION WITH RADIATION OR AZD1775

DDDR-15. UTILIZING DEEP DOCKING AND ARTIFICIAL INTELLIGENCE FOR THE DISCOVERY OF NOVEL PARP1-SELECTIVE INHIBITORS FOR USE AGAINST BRAIN TUMORS

Abstract 2985: Molecular mechanisms of dianhydrogalactitol (VAL-083) in cancer treatment

Abstract B30: Dianhydrogalactitol (VAL-083) has the potential to overcome major challenges in the treatment of DIPG

Abstract B15: Dissecting the molecular mechanism of dianhydrogalactitol (VAL-083) activity in cancer treatment

Suchergebnisse filtern